Brian Hilberdink is Senior Vice President, Sales, at Novo Nordisk
Inc. since September 1, 2020. He is responsible for leading diabetes
and obesity sales and educator team across the country.
Mr. Hilberdink is an accomplished pharmaceutical executive with
over 25 years of global and domestic experience at Novo Nordisk
developing and executing strategy. During his time leading the
diabetes commercial organization, his teams launched the world’s
first oral GLP-1 in the U.S. marketplace and helped create increased
value within the therapeutic category. Before joining Novo Nordisk
Inc. in 2019, he was President of Novo Nordisk Canada. As President
he significantly increased investment in Canada, launched several
innovative products in the therapy areas of diabetes, obesity and
hemophilia, and the company was recognized as one of the country’s
top 100 employers.
Prior to his work at Novo Nordisk Canada, Mr. Hilberdink was a
Corporate Vice President in Global Marketing for Novo Nordisk A/S in
Copenhagen, Denmark, leading the launch of the company’s next
generation insulin portfolio. He also has previous experience working
at Novo Nordisk in the US, where, from 2003 – 2006, he led several
commercial teams during a period of significant growth and investment.
Mr. Hilberdink holds a bachelor’s degree from the Arts &
Science faculty at Queen’s University in Canada and has completed
extensive executive education at multiple universities.